Food and Drug Administration (FDA)

Study: FDA, drugmakers let opioid misuse slide

Oxycodone pain pills. Photo: John Moore/Getty Images

Federal regulators and fentanyl manufacturers didn't take action when it became clear that highly potent fentanyl products were being inappropriately prescribed to as many as half of the patients taking them, according to a new study in the Journal of the American Medical Association.

How it works: The type of fentanyl in question is approved by the Food and Drug Administration only for adult cancer patents who have already built up a tolerance to less potent opioids.

FDA head is open to orphan drug law changes

In this image, FDA commissioner Scott Gottlieb sits with a hand covering his mouth as he frowns into the distance beyond the camera.
FDA Commissioner Scott Gottlieb. Photo: Drew Angerer/Getty Images

FDA Commissioner Scott Gottlieb told Axios that while he thinks the orphan drug market is too small to seriously dampen competition, he's open to changes in the law.

Details: Gottlieb's top priority is giving drugmakers an incentive to develop treatments for the rarest of diseases, or diseases that aren't getting much pharma attention.

More stories loading.